Pembrolizumab (Keytruda)

Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec. This review assesses pembrolizumab (100 mg/4 mL vial solution for IV infusion). Indication: Pembrolizumab in combination with gemcitabine-based chemotherapy is indicated for the treatment of adult patients with locally advanced unresectable or metastatic biliary tract carcinoma.